Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes

Area of Science:

• Hematology
• Pharmacology
• Oncology

Background:

• Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by elevated hematocrit.
• Standard treatment for low-risk PV often involves therapeutic phlebotomy to maintain hematocrit levels.
• Ropeginterferon alfa-2b (Ropeg) is an alternative treatment option with potential benefits in managing PV.

Purpose of the Study:

• To evaluate the long-term efficacy, safety, adherence, and tolerability of Ropeg in low-risk polycythemia vera patients.
• To compare drug survival rates between Ropeg and phlebotomy-only treatment.
• To identify factors influencing treatment failure and inform optimal Ropeg dosing strategies.

Main Methods:

• Analysis of drug survival as a surrogate for efficacy, safety, adherence, and tolerability up to 5 years.
• Comparison of treatment discontinuation rates due to lack of response or adverse events between Ropeg and phlebotomy-only groups.
• Assessment of the primary composite endpoint maintenance in patients continuing Ropeg therapy.

Main Results:

• Ropeg demonstrated superior efficacy over phlebotomy-only, with lower discontinuation rates (33% vs. 70%) in the first 2 years.
• Drug survival probability for Ropeg responders was 59% after a median of 3.15 years.
• The primary composite endpoint was maintained in over 94% of patients on Ropeg at 3-5 years, with 60% being phlebotomy-free.

Conclusions:

• Ropeg is an effective long-term treatment for low-risk polycythemia vera, offering sustained hematocrit control and reducing phlebotomy requirements.
• Early initiation of Ropeg, potentially with increased dosage, may be beneficial, especially in patients with a high phlebotomy need within the first six months.
• High drug survival rates and sustained efficacy suggest Ropeg is a valuable therapeutic option for managing polycythemia vera.